NPPA Caps Trade Margin at 30% for 137 Non-Scheduled Anti-Cancer Drugs, Aims to Save ₹2,500 Crore Annually
How much it matters for each exam
- UPSC7/10
1At a glance
The National Pharmaceutical Pricing Authority (NPPA) has capped the trade margin at 30% for 137 non-scheduled anti-cancer drugs, effective November 9, 2026. The government claims this could save patients about ₹2,500 crore annually, but experts argue it's a tokenistic measure unless structural issues like bulk procurement and manufacturer price control are addressed.
Expanded Price Control
The NPPA has extended trade margin caps from 42 to 137 non-scheduled cancer drugs, aiming to reduce patient costs.
Structural Criticisms
Experts argue the cap is superficial as it doesn't control manufacturer prices or address hidden institutional discounts.
Beyond Drug Prices
The high cost of cancer care includes diagnostics, hospital stays, and procedures, where hospitals can recoup margins lost on drugs.
2Facts to remember
Tap a card to see the answer. Try to recall it first.
3Detailed analysis
Context / Background
Cancer treatment costs in India are prohibitive, with drugs constituting over half the expense. The government's 2019 cap on 42 drugs had limited impact. The new order expands coverage but maintains the same approach of capping trade margins rather than underlying prices, reflecting an ongoing struggle to balance affordability with market realities and pharmaceutical innovation incentives.
Core Analysis & Implications
The 30% cap on PTS translates to a 42.8% mark-up on the stockist price, which critics deem high for expensive drugs. The policy ignores ex-factory costs and institutional bulk purchase discounts, making true savings uncertain. It also excludes Patient Assistance Programme volumes from calculations, potentially masking real trade margins. This could disincentivize generic adoption if hospitals prefer high-margin branded drugs.
Future Outlook / Way Forward
Sustainable solutions require multi-pronged action: using TRIPS flexibilities like compulsory licensing for patented drugs, large-scale government procurement to leverage bargaining power, and transparent pricing based on API cost plus a fixed mark-up. Ultimately, a robust public health system providing free medicines is seen as the most effective solution for equitable access.
4Background GK
Textbook concepts you need to understand this news
- National Pharmaceutical Pricing Authority (NPPA)
- An independent body under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, responsible for controlling the prices of drugs in India under the Drugs (Prices Control) Order (DPCO).
- Trade-Related Aspects of Intellectual Property Rights (TRIPS)
- An international agreement administered by the World Trade Organization (WTO) that sets down minimum standards for intellectual property regulation. It includes flexibilities like compulsory licensing for public health.
- Compulsory Licensing
- A provision under the Indian Patent Act (and TRIPS) that allows the government to permit a third party to produce a patented product without the consent of the patent holder in certain circumstances, such as public health emergencies.
- Price to Stockist (PTS)
- The price at which a pharmaceutical company sells its products to a stockist or wholesaler. It is a key benchmark for calculating maximum retail prices (MRP) under price control policies.
5How exams will ask this
- Data: 137 non-scheduled anti-cancer drugs under new NPPA cap.
- Nodal Body: National Pharmaceutical Pricing Authority (NPPA).
- Legal Point: Compulsory licensing provisions under the Indian Patent Act and TRIPS.
Don't make this mistake!
Confusing 'trade margin cap' with 'price control'. The cap is on the margin between PTS and MRP, not on the manufacturer's selling price. They may also swap the number of drugs covered in the 2019 order (42) with the new order (137).
Write these in mains answers
Trade margin rationalization, TRIPS flexibilities, catastrophic health expenditure, and ethical drug pricing
6Practice questions
Pick an answer, then read the explanation.
- Q1Medium
Consider the following statements regarding the recent NPPA order on cancer drugs:
- 1.It caps the trade margin at 30% on the Price to Stockist for 137 non-scheduled anti-cancer drugs.
- 2.The order is effective from November 9, 2026, and is expected to save patients about ₹2,500 crore annually.
- 3.This is the first-ever price control measure implemented by the NPPA for cancer medicines in India.
Which of the statements given above is/are correct?
Explanation: Statement 1 is correct as per the article. Statement 2 is also correct, citing the effective date and claimed savings. Statement 3 is incorrect because the article mentions a previous cap in 2019 covering 42 drugs. Hence, option C is correct.
- Q2Easy
According to the news, how many non-scheduled anti-cancer drugs were covered under the NPPA's trade margin cap order of 2019?
Explanation: The article explicitly states that the recent order extends a 2019 cap that covered 42 anti-cancer drugs. The new order covers 137 drugs. This is a direct data point for factual recall.
- Q3Medium
What is a major criticism raised by experts regarding the NPPA's trade margin cap on cancer drugs?
Explanation: The article quotes experts like Malini Aisola and S. Srinivasan arguing that the cap is tokenistic as it doesn't control the price at the manufacturing level and excludes data on institutional sales where bulk discounts are negotiated, making actual patient savings uncertain.
7All sources
Original28 October 2026 · Read story